利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.025 秒)

    Therapeutic agents and methods for cardiovascular disease
    6.
    发明申请
    Therapeutic agents and methods for cardiovascular disease 有权
    心血管疾病的治疗剂和方法

    公开(公告)号：US20060074026A1

    公开(公告)日：2006-04-06

    申请号：US11198005

    申请日：2005-08-05

    申请人： Stanley Hazen ,  Marc Penn

    发明人： Stanley Hazen ,  Marc Penn

    IPC分类号： A61K38/10 ,  A61K38/08 ,  A61K38/06

    CPC分类号： C07K16/18 ,  A61K38/1709 ,  C07K14/775 ,  C07K16/40 ,  C07K16/44 ,  G01N2333/775 ,  G01N2333/902 ,  G01N2500/02 ,  G01N2800/32

    摘要： The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding.

    摘要翻译： 本发明提供用于治疗患有或有发展中心或患有心血管疾病的风险的受试者的方法和试剂。 这样的试剂抑制髓过氧化物酶（MPO）与包含载脂蛋白A-1（apoA-1）的MPO结合位点的分子的结合，并且包括在SEQ ID NO：1中包含至少4个连续氨基酸的载脂蛋白-1的肽片段。 NO：2，包含一个或多个D氨基酸的载脂蛋白-1片段的修饰形式，载脂蛋白-A-1肽片段的逆反式形式，载脂蛋白-A-1肽片段的有机模拟物，肽模拟物 的apoA1肽片段，或编码载脂蛋白A-1肽片段的核酸。 本发明还提供鉴定或筛选用于治疗患有或有发生CVD的风险的受试者的方法。 该方法包括在允许MPO与MPO结合位点结合并确定一种或多种药物是否抑制这种结合的条件下，将一种或多种测试剂和MPO与包含apoA-1的MPO结合位点的分子一起孵育。

    Risk markers for cardiovacular disease
    8.
    发明申请
    Risk markers for cardiovacular disease 有权
    心肺疾病的危险标志物

    公开(公告)号：US20050239136A1

    公开(公告)日：2005-10-27

    申请号：US11005563

    申请日：2004-12-06

    申请人： Stanley Hazen ,  Michael Kinter ,  Marc Penn ,  Jonathan Smith ,  Lemin Zheng

    发明人： Stanley Hazen ,  Michael Kinter ,  Marc Penn ,  Jonathan Smith ,  Lemin Zheng

    IPC分类号： A61B20060101 ,  C07K16/18 ,  G01N33/53 ,  G01N33/68 ,  G01N33/92

    CPC分类号： G01N33/561 ,  C07K16/18 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/775 ,  G01N2800/32

    摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

    摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。